drugset / Trial / NCT02854904
Immune Effect of Dexmedetomidine in Patients Undergoing to Spinal Fusion
Phase 2/3
Unknown
46 enrolled
Sarah Network of Rehabilitation Hospitals
University of Brasilia · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Alpha-agonist in anesthesia display immunomodulatory effect in addition to antiadrenergic control. This effect of the immune system can be a key to a better perioperative safety and quality. The association of dexmedetomidine at general anesthesia adds up organic protection and inflammatory control to a surgery trauma owing to antinociception and immunomodulatory effect. The aim this study is evaluate if the association of dexmedetomidine at general anesthesia standing effective immunomodulatory control to trauma and improve changes at outcomes in patients undergoing to spinal fusion.
Timeline
- Start
- 2016-08
- Primary completion
- 2016-11
- Completion
- 2017-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexmedetomidine | Other / unclassified | 0.2 ug/kg | Intravenous |
| Subject | Dexmedetomidine | Other / unclassified | 1 ug/kg | Intravenous |